Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.72 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577826 | 1.00 | PTGS2 (0.72) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL28646419 | 0.92 | PTGS2 (0.71) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL28646416 | 0.84 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL29561416 | 0.84 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL9529 | 0.84 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL6896328 | 0.84 | PTGS2 (0.72) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL5709079 | 0.83 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL28381051 | 0.83 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL117193 | 0.83 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL31213508 | 0.82 | PTGS2 (0.80) | PTGS2NR4A2MT-CO2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM IP INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-118831076-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-113840598-B | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220151972-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM (IP), INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3937925-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM (IP), Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113840598-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2021-12-24 | — | — | CN | disclosed |
| WO-2020186010-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM GROUP, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-7094903-B2 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | ONCONOVA THERAPEUTICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050182113-A1 | Method for preparing diaryl-substituted isoxazole compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-08-18 | — | — | US | disclosed |
| EP-1550658-A1 | Method for preparing 3,4-diphenyl-substituted isoxazole compounds | Dr. Reddy's Laboratories Ltd. (IN) | 2005-07-06 | — | — | EP | disclosed |
| US-20050143583-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | ONCONOVA THERAPEUTICS, INC. (US) | 2005-06-30 | — | — | US | disclosed |
| US-6809204-B2 | HETEROCYCLIC NITROGEN COMPPOUNDS SUCH AS 4-(5-METHYL-3-PHENYL-ISOXAZOL-1-YL)BENZENESULFONAMIDE, USED AS NON-STEROIDAL ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS; CYCLOOXYGENASE INHIBITORS | ONCONOVA THERAPEUTICS, INC. | 2004-10-26 | — | — | US | disclosed |
| US-20030162813-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | ONCONOVA THERAPEUTICS, INC. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | PTGS2 29/4885NR4A2 3088/4885MT-CO2 755/4885 |
| US-20050182113-A1 | Method for preparing diaryl-substituted isoxazole compounds | CYP2C9, CYP3A7, CYP3A5 | PTGS2 75/4885NR4A2 4607/4885MT-CO2 430/4885 |
| US-20050143583-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | F9, HAX1, CYP4X1 | PTGS2 3680/4885NR4A2 3306/4885MT-CO2 679/4885 |
| US-20220151972-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | PTGS2 2331/4885NR4A2 1941/4885MT-CO2 1570/4885 |
| US-20030162813-A1 | Processes for the preparation of substituted isoxazoles and 2-isoxazolines | CYP4X1, HAX1, CYCS | PTGS2 3107/4885NR4A2 2490/4885MT-CO2 213/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | PTGS2 29/4885NR4A2 3088/4885MT-CO2 755/4885 |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | PTGS2 2555/4885NR4A2 1123/4885MT-CO2 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.